Yep, the patients are the most serious refractory patients, so it's not an unexpected outcome that a subject unfortunately passes during the trial. I don't think it would have hurt sentiment to disclose it though. It doesn't relate to dose limiting toxicity (one of the primary safety concerns), so I would've liked to have the additional disclosure.
The combination trial with Onyx and their Kyprolis is a result of the strong response from refractory patients who had previously been resistant to first line of care drugs.
Fingers crossed
Yep, the patients are the most serious refractory patients, so...
Add PAB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
0.4¢ |
Change
0.000(0.00%) |
Mkt cap ! $8.229M | |||
| Open | High | Low | Value | Volume |
| 0.4¢ | 0.5¢ | 0.4¢ | $5.431K | 1.357M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 9 | 26519870 | 0.4¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.5¢ | 7889760 | 12 |
View Market Depth
| Last trade - 11.23am 15/11/2024 (20 minute delay) ? |
| PAB (ASX) Chart |